CN103826631A - 用于治疗视网膜疾病的包含4-溴-n-(咪唑烷-2-亚基)-1h-苯并咪唑-5-胺的药物组合物 - Google Patents

用于治疗视网膜疾病的包含4-溴-n-(咪唑烷-2-亚基)-1h-苯并咪唑-5-胺的药物组合物 Download PDF

Info

Publication number
CN103826631A
CN103826631A CN201280046184.4A CN201280046184A CN103826631A CN 103826631 A CN103826631 A CN 103826631A CN 201280046184 A CN201280046184 A CN 201280046184A CN 103826631 A CN103826631 A CN 103826631A
Authority
CN
China
Prior art keywords
amine
bromo
retinal
patient
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280046184.4A
Other languages
English (en)
Chinese (zh)
Inventor
M·I·迪巴斯
J·E·多纳罗
D·W·吉尔
J·A·伯克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN103826631A publication Critical patent/CN103826631A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280046184.4A 2011-07-22 2012-07-22 用于治疗视网膜疾病的包含4-溴-n-(咪唑烷-2-亚基)-1h-苯并咪唑-5-胺的药物组合物 Pending CN103826631A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161510536P 2011-07-22 2011-07-22
US201161510743P 2011-07-22 2011-07-22
US61/510,536 2011-07-22
US61/510,743 2011-07-22
PCT/US2012/047777 WO2013016252A1 (en) 2011-07-22 2012-07-22 Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases

Publications (1)

Publication Number Publication Date
CN103826631A true CN103826631A (zh) 2014-05-28

Family

ID=46599017

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280046184.4A Pending CN103826631A (zh) 2011-07-22 2012-07-22 用于治疗视网膜疾病的包含4-溴-n-(咪唑烷-2-亚基)-1h-苯并咪唑-5-胺的药物组合物

Country Status (12)

Country Link
US (1) US20130046003A1 (https=)
EP (1) EP2734202A1 (https=)
JP (1) JP2014521648A (https=)
KR (1) KR20140097106A (https=)
CN (1) CN103826631A (https=)
AU (1) AU2012287062A1 (https=)
BR (1) BR112014001538A2 (https=)
CA (1) CA2842756A1 (https=)
IL (1) IL230582A0 (https=)
MX (1) MX2014000870A (https=)
RU (1) RU2014106328A (https=)
WO (1) WO2013016252A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10752593B2 (en) 2018-12-28 2020-08-25 Endogena Therapeutics, Inc. Compounds for use as therapeutically active substances in the treatment of retinal diseases
US10807973B2 (en) 2018-12-28 2020-10-20 Endogena Therapeutics, Inc. Compounds for use as therapeutically active substances in the treatment of retinal diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0775134A4 (en) 1994-08-04 1997-08-13 Synaptic Pharma Corp NEW BENZIMIDAZOLE DERIVATIVES
AU4582797A (en) 1996-09-13 1998-04-02 Regents Of The University Of California, The Methods for treatment of retinal diseases
US6495583B1 (en) 1997-03-25 2002-12-17 Synaptic Pharmaceutical Corporation Benzimidazole derivatives
US20010049369A1 (en) * 2000-02-10 2001-12-06 Jablonski Monica M. Brimonidine compositions and methods for retinal degeneration
AU2002248284A1 (en) * 2000-11-01 2002-08-06 Allergan, Inc. Compositions for treatment of ocular neovascularization
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US20100028266A1 (en) * 2008-08-01 2010-02-04 Alpha Synergy Development. Inc. Composition and methods for treating allergic response
BR112012018154A2 (pt) * 2010-01-21 2016-04-05 Allergan Inc agonista alfa-2 adrenérgico tendo longa duração do efeito de redução da pressão intraocular

Also Published As

Publication number Publication date
US20130046003A1 (en) 2013-02-21
IL230582A0 (en) 2014-03-31
KR20140097106A (ko) 2014-08-06
RU2014106328A (ru) 2015-08-27
JP2014521648A (ja) 2014-08-28
MX2014000870A (es) 2014-06-23
AU2012287062A1 (en) 2014-02-27
EP2734202A1 (en) 2014-05-28
CA2842756A1 (en) 2013-01-31
WO2013016252A1 (en) 2013-01-31
BR112014001538A2 (pt) 2017-02-14

Similar Documents

Publication Publication Date Title
EP2262476B1 (en) Drug delivery to the anterior and posterior segments of the eye using eye drops.
WO2010125416A1 (en) Drug delivery to the anterior and posterior segments of the eye
JP2010536797A5 (https=)
JPH10507743A (ja) 薬剤投与のための方法と手段
CN101842080A (zh) 非水的水混溶性物质作为药物递送的载体
WO2005030221A1 (ja) 加齢黄斑変性治療剤
CN109996814A (zh) 多激酶抑制剂及在眼部纤维化中的用途
CN102770135A (zh) 眼内压降低作用持续时间长的α-2肾上腺素能激动剂
KR102266014B1 (ko) 안질환 예방 또는 치료용 점안 조성물
CN103826631A (zh) 用于治疗视网膜疾病的包含4-溴-n-(咪唑烷-2-亚基)-1h-苯并咪唑-5-胺的药物组合物
JP2007517885A (ja) 眼に投与するためのメマンチンおよびポリアニオン性ポリマーを含む組成物
JP2010260857A (ja) シロリムス誘導体を有効成分として含有する網脈絡膜疾患の治療剤
US20220062255A1 (en) Treatment of neurodegenerative eye disease using pridopidine
AU2019208350A1 (en) Suspension compositions of multi-target inhibitors
JP4838968B2 (ja) 薬物−ポリエチレングリコール結合体を含有する眼組織内注入剤
US20100160342A1 (en) Compositions of Topical Ocular Solutions to Deliver Effective Concentrations of Active Agent to the Posterior Segment of the Eye
WO2001056606A1 (en) Remedies for ophthalmic diseases
US20130267488A1 (en) Pharmaceutical formulation having neuroprotective activity
HK40000005B (zh) 使用尼达尼布改善青光眼手术成功情况的组合物和方法
JP2014533732A (ja) 網膜神経保護のための７−（１ｈ−イミダゾール−４−イルメチル）−５，６，７，８−テトラヒドロ−キノリンを含む医薬組成物
JPWO2023118366A5 (https=)
JP2010100615A (ja) ポリアルキレングリコールを有効成分として含有する網膜疾患の予防又は治療剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140528